Drugmakers are testing a variety of biologics and small molecules in conjunction with therapies aimed at modulating the immune system to target and destroy cancer cells.
Merck, Others Look to Immunotherapy Combos as Next Frontier in Oncology Read More »
La pérdida de peso causada por un medicamento común para la diabetes se vincula con una molécula “contra el hambre” en un estudio
El examen de ADN fecal es una estrategia no invasiva recomendada por varias sociedades profesionales médicas para la detección del cáncer colorrectal en personas de riesgo promedio.
The recall covers respiratory support devices made in 2017 or earlier that can fail to provide enough ventilation.
Vyaire Medical recalls Airlife resuscitators over defect linked to 2 death reports Read More »
In testimony to Congress Thursday, industry and patient group leaders described the trade-offs expected from increased FDA oversight of laboratory-developed tests.
As FDA’s LDT rule looms, experts warn patients may lose access to critical tests Read More »
In a Thursday letter, the American Hospital Association urged the HHS’ Office of Civil Rights to reduce possible “duplicative” breach notifications from the Change cyberattack.
Hospital groups question HHS about data breach reporting after Change attack Read More »
Katherine Truppi will become president of Stryker’s joint replacement business on March 31 after more than 20 years at the company.
Stryker’s next head of joint replacement talks about new revision, robotics products Read More »
Two weeks after the FDA updated Wegovy’s label, Medicare changed its stance to allow people with a history of heart disease to receive treatment, a shift that could further boost access to the fast-selling medicine.
Medicare to cover Novo’s obesity drug for some patients Read More »
New rulings from a U.S. patent appeal board are the latest step in the companies’ dispute over patents for sacral neuromodulation devices.
Medtronic claims win in Axonics patent row, pushes for jury trial Read More »
Duvyzat, which will be sold in the U.S. by ITF Therapeutics, joins a growing market that includes recently approved gene therapy Elevidys and corticosteroid Agamree.
FDA Approves Third Duchenne Muscular Dystrophy Treatment in Nine Months Read More »
